Michael Kenn
Overview
Explore the profile of Michael Kenn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
68
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schreiner W, Karch R, Cibena M, Tomasiak L, Kenn M, Pfeiler G
Comput Struct Biotechnol J
. 2023 Aug;
21:3920-3932.
PMID: 37602229
Molecular mechanisms within the checkpoint receptor PD-1 are essential for its activation by PD-L1 as well as for blocking such an activation via checkpoint inhibitors. We use molecular dynamics to...
2.
Kenn M, Karch R, Singer C, Dorffner G, Schreiner W
J Pers Med
. 2023 Jan;
13(1).
PMID: 36675780
Evidence theory by Dempster-Shafer for determination of hormone receptor status in breast cancer samples was introduced in our previous paper. One major topic pointed out here is the link between...
3.
Kenn M, Karch R, Tomasiak L, Cibena M, Pfeiler G, Koelbl H, et al.
Front Bioeng Biotechnol
. 2022 Oct;
10:838129.
PMID: 36277392
Cells in danger of being erroneously attacked by leucocytes express PD-L1 on their surface. These cells activate PD-1 on attacking leucocytes and send them to death, thus curbing erroneous, autoimmune...
4.
Kenn M, Karch R, Cacsire Castillo-Tong D, Singer C, Koelbl H, Schreiner W
J Pers Med
. 2022 Apr;
12(4).
PMID: 35455687
Estrogen and progesterone receptors being present or not represents one of the most important biomarkers for therapy selection in breast cancer patients. Conventional measurement by immunohistochemistry (IHC) involves errors, and...
5.
Pichler K, Fischer A, Alphonsus J, Chiari C, Schmidt S, Kenn M, et al.
Histochem Cell Biol
. 2021 Nov;
157(2):139-151.
PMID: 34846578
Galectin-4 (Gal-4) is a member of the galectin family, which have been identified as galactose-binding proteins. Gal-4 possesses two tandem repeat carbohydrate recognition domains and acts as a cross-linking bridge...
6.
Kenn M, Cacsire Castillo-Tong D, Singer C, Karch R, Cibena M, Koelbl H, et al.
Sci Rep
. 2021 Feb;
11(1):4233.
PMID: 33608588
Correctly estimating the hormone receptor status for estrogen (ER) and progesterone (PGR) is crucial for precision therapy of breast cancer. It is known that conventional diagnostics (immunohistochemistry, IHC) yields a...
7.
Gruber E, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, et al.
Cells
. 2020 Dec;
9(12).
PMID: 33371531
The authors wish to make the following change to their paper [...].
8.
Kenn M, Cacsire Castillo-Tong D, Singer C, Cibena M, Kolbl H, Schreiner W
Biomed Res Int
. 2020 Aug;
2020:1363827.
PMID: 32832541
Precision medicine for breast cancer relies on biomarkers to select therapies. However, the reliability of biomarkers drawn from gene expression arrays has been questioned and calls for reassessment, in particular...
9.
Gruber E, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, et al.
Cells
. 2019 Nov;
8(11).
PMID: 31671695
AF1q impairs survival in hematologic and solid malignancies. AF1q expression is associated with tumor progression, migration, and chemoresistance, and acts as a transcriptional co-activator in WNT and STAT signaling. This...
10.
Kenn M, Cacsire Castillo-Tong D, Singer C, Cibena M, Kolbl H, Schreiner W
Breast Cancer Res Treat
. 2018 Aug;
172(2):313-326.
PMID: 30117066
Purpose: Therapeutic decisions in breast cancer patients crucially depend on the status of estrogen receptor, progesterone receptor and HER2, obtained by immunohistochemistry (IHC). These are known to be inaccurate sometimes,...